# Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

> **NCT03187678** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 20 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** i.v. selexipag
- **DRUG:** oral selexipag (Uptravi)

## Key facts

- **NCT ID:** NCT03187678
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2018-05-29
- **Final completion:** 2018-05-29
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03187678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03187678, "Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03187678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*